251 related articles for article (PubMed ID: 27082580)
1. Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study.
Fangbin Z; Xiang G; Liang D; Hui L; Xueding W; Baili C; Huichang B; Yinglian X; Peng C; Lizi Z; Yanjun C; Feng X; Minhu C; Min H; Pinjin H
Medicine (Baltimore); 2016 Apr; 95(15):e3326. PubMed ID: 27082580
[TBL] [Abstract][Full Text] [Related]
2. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
3. Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
Kang B; Kim TJ; Choi J; Baek SY; Ahn S; Choi R; Lee SY; Choe YH
Aliment Pharmacol Ther; 2020 Aug; 52(3):459-470. PubMed ID: 32598049
[TBL] [Abstract][Full Text] [Related]
4. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
5. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
[TBL] [Abstract][Full Text] [Related]
7. Measurement of red blood cell 6-thioguanine nucleotide is beneficial in azathioprine maintenance therapy of Chinese Crohn's disease patients.
Liu Q; Wang Y; Mei Q; Han W; Hu J; Hu N
Scand J Gastroenterol; 2016 Sep; 51(9):1093-9. PubMed ID: 27152547
[TBL] [Abstract][Full Text] [Related]
8. Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine.
Lee MN; Kang B; Choi SY; Kim MJ; Woo SY; Kim JW; Choe YH; Lee SY
Inflamm Bowel Dis; 2015 May; 21(5):1054-62. PubMed ID: 25851563
[TBL] [Abstract][Full Text] [Related]
9. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.
Cuffari C; Dassopoulos T; Turnbough L; Thompson RE; Bayless TM
Clin Gastroenterol Hepatol; 2004 May; 2(5):410-7. PubMed ID: 15118980
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations.
Lennard L; Van Loon JA; Lilleyman JS; Weinshilboum RM
Clin Pharmacol Ther; 1987 Jan; 41(1):18-25. PubMed ID: 3467886
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD.
van Gennep S; Konté K; Meijer B; Heymans MW; D'Haens GR; Löwenberg M; de Boer NKH
Aliment Pharmacol Ther; 2019 Sep; 50(5):484-506. PubMed ID: 31342537
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Study Evaluating Metabolic Capacity of Thiopurine and Associated Adverse Reactions in Japanese Patients with Inflammatory Bowel Disease (IBD).
Odahara S; Uchiyama K; Kubota T; Ito Z; Takami S; Kobayashi H; Saito K; Koido S; Ohkusa T
PLoS One; 2015; 10(9):e0137798. PubMed ID: 26360046
[TBL] [Abstract][Full Text] [Related]
14. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
Gao X; Zhang FB; Ding L; Liu H; Wang XD; Chen BL; Bi HC; Xiao YL; Zhao LZ; Chen MH; Huang M; Hu PJ
Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):958-64. PubMed ID: 22664938
[TBL] [Abstract][Full Text] [Related]
15. Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine.
Bayoumy AB; Mulder CJJ; Loganayagam A; Sanderson JD; Anderson S; Boekema PJ; Derijks LJJ; Ansari AR
Ther Drug Monit; 2021 Oct; 43(5):617-623. PubMed ID: 34521801
[TBL] [Abstract][Full Text] [Related]
16. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
[TBL] [Abstract][Full Text] [Related]
17. Monitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel disease.
Kim MJ; Lee SY; Choe YH
Yonsei Med J; 2014 Sep; 55(5):1289-96. PubMed ID: 25048487
[TBL] [Abstract][Full Text] [Related]
18. Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population.
Hindorf U; Peterson C; Almer S
Ther Drug Monit; 2004 Dec; 26(6):673-8. PubMed ID: 15570193
[TBL] [Abstract][Full Text] [Related]
19. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease.
Takatsu N; Matsui T; Murakami Y; Ishihara H; Hisabe T; Nagahama T; Maki S; Beppu T; Takaki Y; Hirai F; Yao K
J Gastroenterol Hepatol; 2009 Jul; 24(7):1258-64. PubMed ID: 19682195
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.
Derijks LJ; Gilissen LP; Engels LG; Bos LP; Bus PJ; Lohman JJ; Curvers WL; Van Deventer SJ; Hommes DW; Hooymans PM
Ther Drug Monit; 2004 Jun; 26(3):311-8. PubMed ID: 15167634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
